Summary
Bristol Myers Squibb Company (BMY) has announced the successful completion of a significant public offering of €5.00 billion in aggregate principal amount of senior unsecured notes, issued by its wholly-owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises notes with maturities ranging from 2030 to 2055 and interest rates from 2.973% to 4.581%. These notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company. The primary purpose of this capital raise is to fund the company's tender offer to repurchase various series of its outstanding notes, as well as to cover associated fees and expenses. Any remaining proceeds will be allocated for general corporate purposes. This debt issuance signifies a strategic move by Bristol Myers Squibb to manage its existing debt obligations and optimize its capital structure.
Key Highlights
- 1BMY subsidiary completed a €5.00 billion public offering of senior unsecured notes.
- 2The notes have varying maturities from 2030 to 2055 with interest rates ranging from 2.973% to 4.581%.
- 3The notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company.
- 4Proceeds will primarily be used to fund a tender offer for outstanding company notes.
- 5The debt issuance is part of BMY's capital management strategy.
- 6The offering was made pursuant to a prospectus supplement filed on November 7, 2025.